TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine – Yahoo Finance

Its sales revenue in 2011 is US $740 million (RMB 4.8 billion). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line.  ZMC’s Lai Li Xin, a branded levofloxacin, is one of the top …

Leave a Reply

Your email address will not be published.

*